INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety and proof-of-concept data to be presented at a scientific meeting in 1H 2025
Press Release: Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies - Newscast
Sat, 19 Apr 2025 20:00:00 GMT PHILADELPHIA, PA — Interius BioTherapeutics has announced its participation in three key scientific gatherings this spring, where the company will spotlight its advancements in in vivo gene and cell ...
Wed, 16 Apr 2025 20:01:00 GMT Interius BioTherapeutics is a clinical stage biotechnology company engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an array of challenging ...
Fri, 25 Oct 2024 05:12:00 GMT PHILADELPHIA, PA — Interius BioTherapeutics has taken a significant ... offering a single-dose, off-the-shelf solution that could be more accessible to patients. The innovative approach of ...
